Jan Peveling-Oberhag

Summary

Affiliation: Johann Wolfgang Goethe University
Country: Germany

Publications

  1. doi request reprint Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection
    J Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    Leukemia 26:1654-62. 2012
  2. doi request reprint Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study
    Jan Peveling-Oberhag
    JW Goethe University Hospital, Frankfurt, Germany
    Clin Ther 35:215-25. 2013
  3. doi request reprint Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs
    J Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    J Viral Hepat 20:234-9. 2013
  4. doi request reprint Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
    Jan Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    J Hepatol 59:169-77. 2013
  5. pmc Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    PLoS ONE 6:e26971. 2011
  6. pmc Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers
    Verena Köberle
    Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
    PLoS ONE 8:e75184. 2013
  7. doi request reprint Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    Am J Gastroenterol 106:1663-9. 2011
  8. doi request reprint Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation
    Jan Peveling-Oberhag
    Department of Medicine I, J W Goethe University Hospital, Frankfurt, Germany
    Med Microbiol Immunol 199:1-10. 2010

Collaborators

Detail Information

Publications8

  1. doi request reprint Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection
    J Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    Leukemia 26:1654-62. 2012
    ..0016). In conclusion, there is a characteristic dysregulation of miRNA expression in SMZL with a possible implication in its molecular tumorigenesis...
  2. doi request reprint Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study
    Jan Peveling-Oberhag
    JW Goethe University Hospital, Frankfurt, Germany
    Clin Ther 35:215-25. 2013
    ..Although the pharmacokinetics of everolimus, an oral mammalian target of rapamycin inhibitor, have been characterized in patients with moderate hepatic impairment, they have not been assessed in those with mild or severe hepatic impairment...
  3. doi request reprint Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs
    J Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    J Viral Hepat 20:234-9. 2013
    ..Further studies are needed to confirm HBV quasispecies evolution as additional predictive marker for beneficial treatment outcome...
  4. doi request reprint Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
    Jan Peveling-Oberhag
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    J Hepatol 59:169-77. 2013
    ..This review systematically summarizes the data on epidemiology, interventional studies, and molecular mechanisms of HCV-associated B-NHL...
  5. pmc Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    PLoS ONE 6:e26971. 2011
    ..Here we correlated serum miR-21 levels with clinical parameters in patients with different stages of chronic hepatitis C virus infection (CHC) and CHC-associated HCC...
  6. pmc Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers
    Verena Köberle
    Department of Medicine I, University Hospital Frankfurt, Frankfurt, Germany
    PLoS ONE 8:e75184. 2013
    ..The consequences of their differential association with lipids/vesicles for their stability and use as biomarkers are largely unexplored and are subject of the present study...
  7. doi request reprint Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    Am J Gastroenterol 106:1663-9. 2011
    ..Here, we investigated if the serum levels of miR-122 might be useful as disease parameter in patients with chronic hepatitis C virus (HCV) infection...
  8. doi request reprint Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation
    Jan Peveling-Oberhag
    Department of Medicine I, J W Goethe University Hospital, Frankfurt, Germany
    Med Microbiol Immunol 199:1-10. 2010
    ..Moreover, upcoming new treatment approaches, e.g. specifically targeted antiviral therapy for hepatitis C (STAT-C) with HCV-specific polymerase and protease inhibitors, may represent a therapeutic alternative...